BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martino M, Recchia AG, Fedele R, Neri S, Vincelli ID, Moscato T, Gentile M, Morabito F. The role of tandem stem cell transplantation for multiple myeloma patients. Expert Opin Biol Ther 2016;16:515-34. [PMID: 26698133 DOI: 10.1517/14712598.2016.1136285] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Morabito F, Tripepi G, Martino EA, Vigna E, Mendicino F, Morabito L, Todoerti K, Al-Janazreh H, D'Arrigo G, Canale FA, Cutrona G, Neri A, Martino M, Gentile M. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma. Drug Des Devel Ther 2021;15:2969-78. [PMID: 34262262 DOI: 10.2147/DDDT.S295215] [Reference Citation Analysis]
2 Ziogas DC, Terpos E, Dimopoulos MA. When to recommend a second autograft in patients with relapsed myeloma? Leuk Lymphoma 2017;58:781-7. [PMID: 27894207 DOI: 10.1080/10428194.2016.1246729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Tang S, Lu Y, Zhang P, Chen D, Liu X, Du X, Cao J, Ye P, Chen L, Li S, Sha K, Zhuang XX, Xie Y, Wu X, Pei R. Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma. Leuk Res 2021;110:106710. [PMID: 34619433 DOI: 10.1016/j.leukres.2021.106710] [Reference Citation Analysis]
4 Sneyd MJ, Gray AR, Morison IM. Trends in survival from myeloma, 1990-2015: a competing risks analysis. BMC Cancer 2021;21:821. [PMID: 34271862 DOI: 10.1186/s12885-021-08544-7] [Reference Citation Analysis]
5 Deng J, Park D, Wang M, Nooka A, Deng Q, Matulis S, Kaufman J, Lonial S, Boise LH, Galipeau J, Deng X. BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget 2016;7:27753-63. [PMID: 27049723 DOI: 10.18632/oncotarget.8513] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
6 Lysak D, Brychtová M, Leba M, Čedíková M, Georgiev D, Jindra P, Vlas T, Holubova M. Long-Term Cryopreservation Does Not Affect Quality of Peripheral Blood Stem Cell Grafts: A Comparative Study of Native, Short-Term and Long-Term Cryopreserved Haematopoietic Stem Cells. Cell Transplant 2021;30:9636897211036004. [PMID: 34328022 DOI: 10.1177/09636897211036004] [Reference Citation Analysis]
7 Randall K, Kaparou M, Xenou E, Paneesha S, Kishore B, Kanellopoulos A, Lovell R, Holder K, Suhr J, Baker L, Ryan L, Nikolousis E. Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant. Eur J Haematol 2017;99:300-5. [PMID: 28632322 DOI: 10.1111/ejh.12917] [Reference Citation Analysis]
8 Martino M, Recchia AG, Console G, Gentile M, Cimminiello M, Gallo GA, Ferreri A, Naso V, Irrera G, Messina G, Moscato T, Vigna E, Vincelli ID, Morabito F. Can we improve the conditioning regimen before autologous stem cell transplantation in multiple myeloma? Expert Opinion on Orphan Drugs 2017;5:875-87. [DOI: 10.1080/21678707.2017.1387050] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
9 Martino M, Rossi M, Ferreri A, Loteta B, Morabito A, Moscato T, Console G, Innao V, Naso V, Provenzano PF, Recchia AG, Gentile M. Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials. Expert Rev Hematol 2019;12:665-84. [PMID: 31251688 DOI: 10.1080/17474086.2019.1634541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]